Abstract 4849: CAP-100: first-in-class anti-CCR7 antibody for CLL

Cuesta-Mateos, Carlos; Muñoz‐Calleja, Cecilia; Loscertales, Javier; Terrón, Fernando; Mol, Wim

doi:10.1158/1538-7445.sabcs18-4849

Search citation statements

Order By: Relevance

Paper Sections

Select...

Ccr7 As a Novel Therapeutic Target In Cll1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2021

Publication Types

Select...

Article1

Relationship

Self Cite1

Independent0

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite not being clear if this molecule blocks the target, the fact that it is linked to a cytotoxic molecule (antibody-drug-conjugate, ADC) indicates that killing tumor cells by means of the release of cytotoxic payloads seems its main MOA. In addition, Catapult Therapeutics disclosed first pre-clinical results of a novel humanized IgG1 antagonist (CAP-100) specifically developed for cancer therapy which will be evaluated in a first-in-human clinical trial (NCT04704323) in 2021 ( 203 , 204 ). This antibody is featured by a unique dual MOA which relies on an effective combination of strong blocking and killing activities.…”

Section: Ccr7 As a Novel Therapeutic Target In Cllmentioning

confidence: 99%

Of Lymph Nodes and CLL Cells: Deciphering the Role of CCR7 in the Pathogenesis of CLL and Understanding Its Potential as Therapeutic Target

Cuesta-Mateos

Brown

Terrón³

et al. 2021

Front. Immunol.

Self Cite

View full text Add to dashboard Cite

The lymph node (LN) is an essential tissue for achieving effective immune responses but it is also critical in the pathogenesis of chronic lymphocytic leukemia (CLL). Within the multitude of signaling pathways aberrantly regulated in CLL the homeostatic axis composed by the chemokine receptor CCR7 and its ligands is the main driver for directing immune cells to home into the LN. In this literature review, we address the roles of CCR7 in the pathophysiology of CLL, and how this chemokine receptor is of critical importance to develop more rational and effective therapies for this malignancy.

show abstract

Section: Ccr7 As a Novel Therapeutic Target In Cllmentioning

confidence: 99%